Gender Selection and IVF in Europe: Where It's Legal and What It Costs

Last updated: January 2026

Gender selection for non-medical reasons is illegal in every EU member state. EU Directive 2004/23/EC on human tissues and cells, combined with national legislation, prohibits choosing an embryo’s sex for family balancing or parental preference. Every country that allows PGT-A (chromosomal screening) draws the same line: you can screen embryos for health conditions, but you cannot select based on sex.

That’s the rule. Here’s where it gets complicated.

The Medical Exception

Every European country that allows genetic testing on embryos permits sex selection for one reason: preventing sex-linked genetic conditions. If you or your partner carry a gene for Duchenne muscular dystrophy, hemophilia A, fragile X syndrome, or another condition that disproportionately affects one sex, clinics in Spain, the UK, Greece, Belgium, and others can test and select embryos accordingly.

This is PGT-M (preimplantation genetic testing for monogenic disorders), not the broader PGT-A screening. The distinction matters legally. PGT-M for a specific known condition is permitted almost everywhere in Europe. PGT-A (which reveals sex as a byproduct of chromosomal screening) is banned in Germany, France, Denmark, and the Netherlands.

In countries where PGT-A is legal (Spain, UK, Greece, Belgium, Italy, Switzerland), embryologists know the sex of every screened embryo. They are legally required not to tell you, and not to use that information in selecting which embryo to transfer. A clinic that selects an embryo based on sex, even when they have the data, is breaking the law.

Where Non-Medical Gender Selection Happens

North Cyprus

North Cyprus is the closest destination to Europe where gender selection is marketed to international patients. Clinics openly advertise it. But the current legal position is more nuanced than the marketing suggests.

The TRNC Ministry of Health now requires that any gender selection use the MicroSort sperm-sorting method (pre-fertilisation), not PGT alone. The rationale: using PGT for sex selection means creating embryos, testing them, then discarding those of the “wrong” sex. The Ministry considers this unethical (North Cyprus IVF Centre, 2025; Cyprus IVF Centre, 2025).

MicroSort separates X-bearing and Y-bearing sperm before fertilisation. Accuracy: approximately 90% for female selection, 75% for male (Genetics & IVF Institute data). It’s not a guarantee.

Cost: An IVF cycle with gender selection in North Cyprus runs EUR 6,500-8,750 depending on the clinic and whether PGT-A is added for chromosomal screening alongside the gender component (Cyprus IVF Centre, 2025; Dunya IVF, 2025).

United States

The US is the main destination for patients who want guaranteed gender selection with ICSI + PGT-A. No federal law prohibits sex selection. The American Society for Reproductive Medicine (ASRM) Ethics Committee considers it ethically permissible for family balancing, though not all clinics offer it (ASRM Ethics Committee Opinion, 2015).

Cost: $18,000-30,000 all-in for an IVF cycle with PGT-A and gender selection in the US. Some clinics offer “gender guarantee” packages with refund terms. The price premium over a standard US IVF cycle ($12,000-15,000 base) is essentially the PGT-A add-on ($3,000-6,000) plus the gender selection consultation fee.

For European patients, that means flying transatlantic. Two trips minimum (one for monitoring, one for retrieval/transfer), plus hotel, flights, and medication. All-in cost easily exceeds $25,000.

Other Destinations

Mexico and Thailand also offer non-medical gender selection via IVF + PGT-A at lower price points than the US ($8,000-15,000). Neither has laws prohibiting it. Thailand’s Protection of Children Born through Assisted Reproductive Technologies Act (2015) restricts gender selection but enforcement is inconsistent.

Turkey bans gender selection. Despite being geographically close to North Cyprus, the legal frameworks are different.

The Legal Map

What It Costs

PGT-A provides near-certain sex identification because it reads the full chromosome complement. MicroSort is probabilistic because it sorts sperm, not embryos. If certainty matters to you, PGT-A is the only method. If PGT-A for sex selection matters to you, Europe is not the place to do it.

The Ethics Debate

ESHRE’s position: sex selection for non-medical reasons is ethically problematic and should not be offered (ESHRE Ethics Taskforce, 2013). The concern is twofold. First, that selecting embryos based on sex implies one sex is more desirable. Second, that normalising sex selection could shift population demographics in countries with existing sex-ratio imbalances.

The ASRM takes a different view, considering family balancing acceptable when a couple already has children of one sex and wants a child of the other.

Both positions have merit. Europe chose one path, the US chose another. Your options depend on where you’re willing to travel.

Browse all Cyprus clinics → | Compare PGT-A laws → | Find your clinic →

Sources

1. EU Directive 2004/23/EC on standards of quality and safety for human tissues and cells.
2. ESHRE Ethics Taskforce. “Cross-border reproductive care.” Human Reproduction, 2013.
3. ASRM Ethics Committee. “Use of reproductive technology for sex selection for nonmedical reasons.” Fertility and Sterility, 2015.
4. North Cyprus IVF Centre. Gender selection: https://www.northcyprusivf.com/treatments/gender-selection/
5. Cyprus IVF Centre. Family balancing: https://cyprusivfcentre.com/gender-selection-cyprus-family-balancing/
6. Dunya IVF treatment costs (2025): https://www.dunyaivf.com/en/ivf-treatment-costs/
7. HFEA. Sex selection: https://www.hfea.gov.uk/treatments/embryo-testing-and-treatments-for-disease/
8. PMC: Preimplantation genetic testing legislation across Europe: https://pmc.ncbi.nlm.nih.gov/articles/PMC7197420/